Abstract
The purpose of this paper is to review the early results of Prostalac system under licence from Therapeutic Goods Administration for Professor Howie in the management of two stage exchange hip arthroplasty for infection (restricted to Royal Adelaide Hospital) and the addition of vancomycin and teicoplanin powder to tobramycin cement without additional tobramycin.
Thirteen patients were treated for an infected THR with the Prostalac system. Preoperative and intra-operative cultures were taken to identify the infective organisms. Vancomycin 3 gm was added to the Prostalac cement mantle per 40 gm packet of antibiotic bone cement containing tobramycin 1 gm. Teicoplanin 2.4 gm was used in one case where the patient had a known vancomycin allergy. Postoperatively patients underwent six weeks of IV antibiotics followed by four to six weeks of oral.
A short term successful clinical outcome was determined by implantation of a total hip prosthesis at the time of second stage operation and no reoperations resulting from recurrent infection and off antibiotics for â□¥ 6 months with normal clinical and CRP lab values.
Thirteen patients received the Prostalac system. No patient was lost to follow-up. Nine have progressed to second stage revision, eight of which had femoral impaction grafting. Two deaths occurred not attributed to the Prostalac system. Three superficial wound infections and two required washout and debridement. One Prostalac stem subsidence. There has been no recurrence of deep joint infection. Retention of the second stage prosthesis has been 100% at 17 months.
The PROSTALAC system with the addition of vancomycin or teicoplanin to the tobramycin antibiotic cement has encouraging short-term results for treatment of deep joint infection. Complication rate has been well within the range reported in literature. Successful early outcomes are encouraging with all patients in the Prostalac study having retained their permanent hip prosthesis following second stage surgery.
